GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SomnoMed Ltd (OTCPK:SOMNF) » Definitions » 9-Day RSI

SOMNF (SomnoMed) 9-Day RSI : 29.08 (As of Mar. 23, 2025)


View and export this data going back to 2016. Start your Free Trial

What is SomnoMed 9-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2025-03-23), SomnoMed's 9-Day RSI is 29.08.

The industry rank for SomnoMed's 9-Day RSI or its related term are showing as below:

SOMNF's 9-Day RSI is ranked better than
68.5% of 892 companies
in the Medical Devices & Instruments industry
Industry Median: 45.335 vs SOMNF: 29.08

Competitive Comparison of SomnoMed's 9-Day RSI

For the Medical Devices subindustry, SomnoMed's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SomnoMed's 9-Day RSI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SomnoMed's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where SomnoMed's 9-Day RSI falls into.



SomnoMed  (OTCPK:SOMNF) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SomnoMed  (OTCPK:SOMNF) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


SomnoMed 9-Day RSI Related Terms

Thank you for viewing the detailed overview of SomnoMed's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


SomnoMed Business Description

Traded in Other Exchanges
Address
20 Clarke Street, Level 3, Crows Nest, Sydney, NSW, AUS, 2065
SomnoMed Ltd produces and sells oral treatment of sleep-related disorder devices. It manufactures and designs premium oral appliances for the treatment of sleep-disordered breathing relieving conditions. Its products include SomnoDent, Som Tabs, Som Morning Repositioner and others. Its geographical segments include North America, Europe, and Asia-Pacific. Business operations consist of the production and sale of products treating sleep-disordered breathing, which is the only reportable segment. Substantial revenue is realized from the European region.

SomnoMed Headlines

From GuruFocus

Full Year 2024 Somnomed Ltd Earnings Call Transcript

By GuruFocus Research 08-29-2024

Half Year 2022 Somnomed Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

Full Year 2022 Somnomed Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

SomnoMed posts record Q4 and delivers on FY22 revenue guidance

By PRNewswire PRNewswire 07-26-2022

Full Year 2020 Somnomed Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

Somnomed Ltd Annual Shareholders Meeting Transcript

By GuruFocus Research 02-15-2024

Full Year 2021 Somnomed Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

Full Year 2023 Somnomed Ltd Earnings Call Transcript

By GuruFocus Research 02-15-2024

SomnoMed's North America Q1 revenue growth leads the way

By PRNewswire PRNewswire 10-28-2022